Bifidobacterium bifidum BGN4

Seqmatch :: Results for Query Sequences under Bacteria

A new anti-cancer polysaccharide from the genus Bifidobacterium

This invention is regarding the anti-cancer activity polysaccharide of 1,400,000 or 1,500,000 molecular weight isolated from the Bifidobacterium, which is known as the probiotic bacteria among bacteria in intestines of humans and animals, the method to separate and refine this polysaccharide, and functional food and pharmaceutical compositions that include this polysaccharide. In detail, this invention is regarding the followings: First, homogenization of heat treated polysaccharide fraction that shows anti cancer activity induced from bifidobacterium Bifidum BGN4. Second, the method to separate and refine anti-cancer active polysaccharide including the homogenization heat treatment, phenol extraction, and concentration using ethanol. Third, various food materials or medicine preparations whose active ingredient is this polysaccharide.

This invention is regarding the method to prevent and treat food allergy by B.bifidum BGN4 as beneficial ingredients and by administering the B.bidum BGN4 containing composition.

Anti-allergy effect [Research data]

Anti-cancerogenic effect

Papers

1. Binding of Aflatoxin B1 to Bifidobacteria In-Vitro.
   Journal of Food Protection, Vol, 63, No.8, 2000, Page 1133-1136
   
   
2. Cytoskeleton Reorganization and Cytokine Production of Macrophage by Bifidobacterial Cells and Cell-Free Extracts.
   J. Microbiol. Biotechnol, (2002), 12(3), 398-405
   
   
3. Characterization of Adhension of Bifidobacterium sp. BGN4 to Human Enteroyte-Like Caco-2 Cells.
   J. Microbiol. Biotechnol, (2003), 13(2), 276-281
   
   
4. Anticancerogenic effect of a novel chiroinositol-containing polysaccharide from Bifidobacterium bifidum BGN4.
   FEMS Microbiology Letters 240 (2004) 131-136
   
   
5. Effect of Bifidobacterium Cell Fractions on IL-6 Production in RAW 264.7 Macrophage Cells.
   J. Microbiol. Biotechnol. (2005), 15(4), 740-774
   
   
6. Effect of Bifidobacteria on Production of Allergy-Related Cytokines from Mouse Spleen Cells.
   J. Microbiol. Biotechnol. (2005), 15(2), 265-268
   
   
7. Oral probiotic bacterial administration suppressed allergic responses in an ovalbumin-induced allergy mouse model.
   FEMS Immunology and Medical Microbiology 2005 Aug 1; 45(2): 259-67
   
   
8. Timing of bifidobacterium administration influences the development of allergy to ovalbumin in mice.
   Biotechnol Lett. 2005 Sep;27(18):1361-7.
   
   
9. Effect of Viability and Integrity of Bifidobacterium on Suppression of Allergy in Mice.
   J. Microbiol. Biotechnol. (2006), 16(7), 1-7825
   
   
10. Modulatory activity of Bifidobacterium sp. BGN4 cell fractions on immune cells.
    J. Microbiol. Biotechnol. 16: 584-589. Kim, N. J. and G. E. Ji. 2006.
    
    
11. Oral feeding of Bifidobacterium bifidum (BGN4) prevents CD4+ CD45RBhigh T cell-mediated inflammatory bowel disease by inhibition of disordered T cell activation.
    Clinical Immunology (2007) 123, 30-39
    
    
12. Probiotics in Primary Prevention of Atopic Dermatitis .
    Forum Nutr. Basel, Karger, 2009, vol 61, pp 117-128

Patents

A new anti-cancer polysaccharide from the genus Bifidobacterium This invention is regarding the anti-cancer activity polysaccharide of 1,400,000 or 1,500,000 molecular weight isolated from the Bifidobacterium, which is known as the probiotic bacteria among bacteria in intestines of humans and animals, the method to separate and refine this polysaccharide, and functional food and pharmaceutical compositions that include this polysaccharide. In detail, this invention is regarding the followings: First, homogenization of heat treated polysaccharide fraction that shows anti cancer activity induced from bifidobacterium Bifidum BGN4. Second, the method to separate and refine anti-cancer active polysaccharide including the homogenization heat treatment, phenol extraction, and concentration using ethanol. Third, various food materials or medicine preparations whose active ingredient is this polysaccharide.

Composition for Prevention and Treatment of Food Allergy containing Bifidobacterium bifidum BGN4 as Active Ingredient This invention is regarding the method to prevent and treat food allergy by B.bifidum BGN4 as beneficial ingredients and by administering the B.bidum BGN4 containing composition.

S-adenosyl-methionine supplemented functional yogurt and method for its manufacture

This invention is regarding the method of manufacturing a functional yogurt that is supplemented the natural SAM(S-adenosyl-methionine) by using BIF BIFIDUM BGN4 lactic bacterium that contains high content of SAM in its cell and in more detail regarding the method to select the bacteria that have high content of SAM in their cells in order to supplement natural SAM that has many physiological activation effect such as the effect of improving the hypocondria.